[go: up one dir, main page]

PE20150666A1 - Inhibidores de serina/treonina cinasa - Google Patents

Inhibidores de serina/treonina cinasa

Info

Publication number
PE20150666A1
PE20150666A1 PE2014001344A PE2014001344A PE20150666A1 PE 20150666 A1 PE20150666 A1 PE 20150666A1 PE 2014001344 A PE2014001344 A PE 2014001344A PE 2014001344 A PE2014001344 A PE 2014001344A PE 20150666 A1 PE20150666 A1 PE 20150666A1
Authority
PE
Peru
Prior art keywords
serine
kinase inhibitors
threonine kinase
compounds
hyperproliferative
Prior art date
Application number
PE2014001344A
Other languages
English (en)
Inventor
James F Blake
Mark Joseph Chicarelli
Rustam Ferdinand Garrey
John Gaudino
Jonas Grina
David A Moreno
Peter J Mohr
Li Ren
Jacob Schwarz
Huifen Chen
Kirk Robarge
Aihe Zhou
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of PE20150666A1 publication Critical patent/PE20150666A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion describe compuestos de formula l: o estereoisomeros, tautomeros, profarmacos o sales farmaceuticamente aceptables de los mismos, en la que R1, R2, R3, R4, X1, X2, Y1 y Y2 se definen en la presente solicitud. Estos compuestos son activos como inhibidores de serina/treonina cinasa, por lo que son utiles en el tratamiento de enfermedades hiperproliferativas e inflamatorias.
PE2014001344A 2012-03-01 2013-03-01 Inhibidores de serina/treonina cinasa PE20150666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261605523P 2012-03-01 2012-03-01

Publications (1)

Publication Number Publication Date
PE20150666A1 true PE20150666A1 (es) 2015-05-06

Family

ID=47892024

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001344A PE20150666A1 (es) 2012-03-01 2013-03-01 Inhibidores de serina/treonina cinasa

Country Status (37)

Country Link
US (4) US8697715B2 (es)
EP (2) EP2820009B1 (es)
JP (2) JP6068515B2 (es)
KR (1) KR102093526B1 (es)
CN (2) CN104507926B (es)
AR (2) AR090220A1 (es)
AU (1) AU2013225737B2 (es)
BR (1) BR112014021634B1 (es)
CA (1) CA2866086C (es)
CL (1) CL2014002301A1 (es)
CO (1) CO7081155A2 (es)
CR (1) CR20140413A (es)
CY (1) CY1120172T1 (es)
DK (2) DK3321262T3 (es)
ES (2) ES2857649T3 (es)
HK (3) HK1204323A1 (es)
HR (2) HRP20180591T1 (es)
HU (2) HUE053994T2 (es)
IL (2) IL234376A (es)
LT (2) LT3321262T (es)
MX (1) MX354675B (es)
MY (1) MY191936A (es)
NO (1) NO2945854T3 (es)
NZ (1) NZ700314A (es)
PE (1) PE20150666A1 (es)
PH (3) PH12015501654A1 (es)
PL (2) PL3321262T3 (es)
PT (2) PT2820009T (es)
RS (2) RS57097B1 (es)
RU (1) RU2650501C2 (es)
SG (1) SG11201405356QA (es)
SI (2) SI3321262T1 (es)
SM (1) SMT201800282T1 (es)
TW (1) TWI589569B (es)
UA (1) UA116774C2 (es)
WO (1) WO2013130976A1 (es)
ZA (2) ZA201406688B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013021896A2 (pt) 2011-02-28 2016-11-08 Array Biopharma Inc inibidores de serina/treonina cinase
RU2014108140A (ru) 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
JP6068515B2 (ja) 2012-03-01 2017-01-25 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
MX363118B (es) * 2012-05-03 2019-03-11 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
MX369989B (es) 2012-08-27 2019-11-27 Array Biopharma Inc Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2884766A1 (en) 2012-10-16 2014-04-24 Daniel Jon Burdick Serine/threonine kinase inhibitors
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
SI3063143T1 (sl) 2013-11-01 2018-09-28 Novartis Ag, Aminoheteroaril benzamidi kot inhibitorji kinaze
BR112016012844B1 (pt) * 2013-12-06 2023-01-10 Genentech, Inc Composto e composições farmacêuticas
BR112016015235A2 (pt) * 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
WO2015103137A1 (en) 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
TWI762806B (zh) 2014-04-09 2022-05-01 美商建南德克公司 作為ｅｒｋ抑制劑之化合物
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
WO2016106009A1 (en) 2014-12-22 2016-06-30 Eli Lilly And Company Erk inhibitors
CN106536522B (zh) * 2015-06-03 2020-08-28 捷思英达医药技术（上海）有限公司 用于治疗银屑病的杂环化合物
WO2016192063A1 (en) * 2015-06-03 2016-12-08 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as erk inhibitors
ES2989326T3 (es) 2015-10-21 2024-11-26 Otsuka Pharma Co Ltd Compuestos de benzolactama como inhibidores de la proteína cinasa
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
CR20180316A (es) 2015-11-09 2018-10-05 Astrazeneca Ab Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
UA126231C2 (uk) 2016-06-16 2022-09-07 Деналі Терапьютікс Інк. Піримідин-2-іламіно-1н-піразоли як інгібітори lrrk2 для застосування при лікуванні нейродегенеративних захворювань
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CN111032656B (zh) * 2017-08-22 2022-12-02 捷思英达医药技术（上海）有限公司 杂环化合物激酶抑制剂及其药物组合物和应用
CA3073073A1 (en) 2017-09-08 2019-03-14 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
CN111433195B (zh) 2017-11-24 2023-04-25 诺华股份有限公司 吡啶酮衍生物及其作为选择性alk-2抑制剂的用途
ES2936627T3 (es) * 2018-02-08 2023-03-21 Zhangzhou Pien Tze Huang Pharm Compuesto de pirazina-2(1H)-cetona como inhibidor de FGFR
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US12133841B2 (en) 2018-05-22 2024-11-05 Js Innomed Holdings Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020192750A1 (zh) * 2019-03-28 2020-10-01 江苏恒瑞医药股份有限公司 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
CN113784970B (zh) * 2019-05-15 2022-11-29 南京明德新药研发有限公司 Erk抑制剂及其应用
EP4011885A4 (en) 2019-08-02 2023-01-18 Wellmarker Bio Co., Ltd. CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
WO2022100586A1 (zh) * 2020-11-11 2022-05-19 南京明德新药研发有限公司 一种含氧杂环丁烷的螺环类化合物的晶型、制备方法及其应用
CN115413669B (zh) * 2022-06-14 2024-03-15 湖南大学 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5705502A (en) * 1993-10-01 1998-01-06 Novartis Corporation Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
HUP0001140A3 (en) 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
RU2277911C2 (ru) 2000-02-25 2006-06-20 Ф.Хоффманн-Ля Рош Аг Модуляторы аденозиновых рецепторов
US7189717B2 (en) 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
US7214685B2 (en) 2000-05-02 2007-05-08 Lutz F. Tietze Prodrugs for a selective cancer therapy
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (es) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
NZ534395A (en) * 2002-02-14 2006-10-27 Pharmacia Corp Substituted pyridinones as modulators of p38 MAP kinase
CA2485166A1 (en) * 2002-05-21 2003-12-04 Amgen Inc. Substituted pyrimidinone and pyridinone compounds
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CA2490818A1 (en) 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
NL1026826C2 (nl) * 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
AU2005232745A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US20080187575A1 (en) 2004-08-27 2008-08-07 Bert Klebl Pyrimidine Derivatives
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
ATE485268T1 (de) 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
KR20090052884A (ko) 2006-08-23 2009-05-26 화이자 프로덕츠 인크. Ｇｓｋ-3 억제제로서의 피리미돈 화합물
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
SI2121674T1 (sl) 2007-02-01 2010-09-30 Tibotec Pharm Ltd Postopki in intermediati za pripravo makrocikličnega proteaznega inhibitorja HCV
US8273759B2 (en) 2007-06-08 2012-09-25 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
JP5611826B2 (ja) 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン
EP2205086B1 (en) 2007-11-06 2013-08-14 E. I. du Pont de Nemours and Company Fungicidal heterocyclic amines
WO2009105500A1 (en) 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
KR20110022089A (ko) 2008-06-27 2011-03-04 노파르티스 아게 유기 화합물
DK2370413T3 (en) * 2008-12-08 2015-11-02 Arena Pharm Inc Modulators of prostacyclin (PG12) receptor, which can be used for the treatment of disorders related to this
DE102009051799B4 (de) 2009-11-03 2021-07-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bifunktionale Prodrugs und Drugs
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
BR112013021896A2 (pt) 2011-02-28 2016-11-08 Array Biopharma Inc inibidores de serina/treonina cinase
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
RU2014108140A (ru) 2011-08-04 2015-09-10 Эррэй Биофарма Инк. Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
JP6068515B2 (ja) * 2012-03-01 2017-01-25 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
MX369989B (es) 2012-08-27 2019-11-27 Array Biopharma Inc Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas.
KR102244553B1 (ko) 2013-08-23 2021-04-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 용량 소자 및 반도체 장치
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
BR112016015235A2 (pt) * 2013-12-30 2017-08-08 Genentech Inc Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
WO2015103137A1 (en) * 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
TWI762806B (zh) * 2014-04-09 2022-05-01 美商建南德克公司 作為ｅｒｋ抑制劑之化合物

Also Published As

Publication number Publication date
SG11201405356QA (en) 2014-11-27
US9259470B2 (en) 2016-02-16
CO7081155A2 (es) 2014-10-10
KR102093526B1 (ko) 2020-03-25
US10519126B2 (en) 2019-12-31
ZA201508847B (en) 2023-01-25
JP2015508828A (ja) 2015-03-23
RU2014139601A (ru) 2016-04-20
CN104507926B (zh) 2016-08-31
DK3321262T3 (da) 2021-01-25
CL2014002301A1 (es) 2015-05-08
HRP20180591T1 (hr) 2018-05-18
JP6068515B2 (ja) 2017-01-25
BR112014021634A8 (pt) 2018-01-30
AU2013225737B2 (en) 2018-03-01
PH12014501947A1 (en) 2014-11-24
CN104507926A (zh) 2015-04-08
RS61500B1 (sr) 2021-03-31
TWI589569B (zh) 2017-07-01
CR20140413A (es) 2014-11-05
SI3321262T1 (sl) 2021-04-30
CA2866086C (en) 2020-06-09
MX354675B (es) 2018-03-15
EP2820009B1 (en) 2018-01-31
RS57097B1 (sr) 2018-06-29
DK2820009T3 (en) 2018-04-16
PH12015501653A1 (en) 2017-04-10
US20180127393A1 (en) 2018-05-10
PH12015501653B1 (en) 2018-01-17
CA2866086A1 (en) 2013-09-06
HK1206011A1 (en) 2015-12-31
ZA201406688B (en) 2017-08-30
HK1254429A1 (zh) 2019-07-19
CN106349217B (zh) 2020-08-28
EP2820009A1 (en) 2015-01-07
AR090220A1 (es) 2014-10-29
LT3321262T (lt) 2021-06-10
US9708290B2 (en) 2017-07-18
CY1120172T1 (el) 2018-12-12
US8697715B2 (en) 2014-04-15
WO2013130976A1 (en) 2013-09-06
HRP20210482T1 (hr) 2021-05-14
IL244276A0 (en) 2016-04-21
MX2014010432A (es) 2015-02-04
UA116774C2 (uk) 2018-05-10
SMT201800282T1 (it) 2018-07-17
PH12015501654B1 (en) 2017-04-10
PH12015501654A1 (en) 2017-04-10
HK1204323A1 (en) 2015-11-13
BR112014021634B1 (pt) 2022-09-27
IL234376A (en) 2016-10-31
JP2016027053A (ja) 2016-02-18
MY191936A (en) 2022-07-19
RU2650501C2 (ru) 2018-04-16
PT2820009T (pt) 2018-04-12
KR20140138820A (ko) 2014-12-04
CN106349217A (zh) 2017-01-25
NO2945854T3 (es) 2018-07-21
EP3321262B1 (en) 2021-01-13
LT2820009T (lt) 2018-05-10
PL3321262T3 (pl) 2021-06-28
ES2857649T3 (es) 2021-09-29
AR121879A2 (es) 2022-07-20
SI2820009T1 (en) 2018-05-31
HUE053994T2 (hu) 2021-08-30
NZ700314A (en) 2016-08-26
US20140249127A1 (en) 2014-09-04
PL2820009T3 (pl) 2018-09-28
IL244276B (en) 2020-01-30
HUE037423T2 (hu) 2018-08-28
EP3321262A1 (en) 2018-05-16
PH12014501947B1 (en) 2014-11-24
TW201339146A (zh) 2013-10-01
US20130252934A1 (en) 2013-09-26
ES2665073T3 (es) 2018-04-24
PT3321262T (pt) 2021-03-04
US20160122316A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
PE20150666A1 (es) Inhibidores de serina/treonina cinasa
UY39630A (es) Inhibidores de bromodominios
ECSP18083519A (es) Inhibidores de bromodominios
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
PE20150669A1 (es) Derivados de benzamida para la inhibicion de la actividad de abl1, abl2 y bcr-abl1
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CR20160035A (es) Inhibidores de bromodominios
MX379474B (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
CO7180199A2 (es) Imidazotriazincarbonitrilos útiles como inhibidores de cinasa
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
ECSP12012083A (es) Pirrolidina-2-carboxamidas sustituidas
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
IN2015DN00598A (es)
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
MX368178B (es) Compuestos de ácido dimetilbenzoico.
GB201209587D0 (en) Therapeutic compounds
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MX2016004841A (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).

Legal Events

Date Code Title Description
FG Grant, registration